Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.
Candlestick & Bollinger Bands
News Feed
- Neos Therapeutics Inc. advanced stock charts by MarketWatch. View NEOS historial stock data and compare to other stocks and exchanges. More
- Shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) gapped up prior to trading on Wednesday . The stock had previously closed at $0.50, but opened at $0.57. Neos Therapeutics shares last traded at $0.51, with a volume of 2,581 shares. Separately, Zacks Investment Research downgraded shares of Neos Therapeutics from a hold rating to a sell rating [] More
- Several other retailers and brands have vowed to stop selling fur, but Nordstrom is the first retailer to also ban exotic skins. More
- GRAND PRAIRIE, Texas (AP) _ Neos Therapeutics Inc. (NEOS) on Friday reported a loss of $3.5 million in its fourth quarter. The Grand Prairie, Texas-based company said it had a loss of 7 cents per share. The pharmaceutical company posted revenue of $16.8 million in the period. For the year, the company reported that its loss narrowed to $16.9 million, or 34 cents per share. Revenue was reported as $64.6 million. The company’s shares closed at $1.22. A year ago, they were trading at $2.09. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NEOS at https://www.zacks.com/ap/NEOS More
- Magellan Midstream Partners L.P. (NYSE:MMP) Magellan Midstream Partners L.P. (NYSE:MMP), ended its previous trading session at $59.23 showing a loss of -0 More
©Copyright 2020
5Charts.com